Esperion Therapeutics INC (ESPR) Shareholder Pentwater Capital Management LP Increased Stake

November 10, 2018 - By Clara Lewis

Big Money Sentiment decreased to 0.95 in 2018 Q2. It has change of 0.55, from 2018Q1’s 1.5. The ratio dropped due to ESPR positioning: 43 sold and 35 reduced. 18 funds amassed holdings and 56 increased holdings. Investors holded 24.56 million in 2018Q1 but now own 26.84 million shares or 9.29% more. Trust Of Vermont reported 0% in Esperion Therapeutics, Inc. (NASDAQ:ESPR). Royal Bancorporation Of Canada reported 13,235 shs. Rhenman Prns Asset has 406,361 shs. Metropolitan Life Insurance Ny has invested 0% in Esperion Therapeutics, Inc. (NASDAQ:ESPR). Ubs Asset Mngmt Americas reported 6,100 shs stake. Moreover, Rhumbline Advisers has 0% invested in Esperion Therapeutics, Inc. (NASDAQ:ESPR) for 23,061 shs. Rudman Errol M holds 50,000 shs. State Of Wisconsin Board has invested 0% in Esperion Therapeutics, Inc. (NASDAQ:ESPR). Connor Clark Lunn Investment Management Ltd has invested 0.01% of its capital in Esperion Therapeutics, Inc. (NASDAQ:ESPR). 320,815 are owned by Amundi Pioneer Asset Mgmt. New York State Common Retirement Fund owns 37,177 shs or 0% of their US capital. Hap Trading Llc holds 10,597 shs or 0.02% of its capital. Northern Tru Corp, a Illinois-based fund reported 591,726 shs. The Switzerland-based Swiss National Bank & Trust has invested 0% in Esperion Therapeutics, Inc. (NASDAQ:ESPR). Wasatch Advsr holds 0.26% or 541,012 shs in its capital.

In 2018Q2 Securities and Exchange filling is reported Pentwater Capital Management Lp’s holdings in Esperion Therapeutics Inc (ESPR) which was rose by 6.64%. The company’s stock rose 15.64% with the market as Pentwater Capital Management Lp bought 153,500 shares. The hedge fund is holding 2.46M shares, compared to the 2.31M from the previous quarter. And the announced value of the health care company is $96.56 million for the 2018Q2. $1.46B is the MC of Esperion Therapeutics Inc. Ticker’s shares touched $54.49 during the last trading session after 6.79% change.Esperion Therapeutics, Inc. is downtrending after having declined 8.71% since November 10, 2017. ESPR has 933,255 volume or 33.46% up from normal. ESPR underperformed by 24.33% the S&P500.

The Pentwater Capital Management Lp’s stake in Broadcom Ltd (Call) was reduced by 220,000 shares to 20,000 shares valued at $4.85M in 2018Q2, according to the filing. It manages about $5.28 billion and $13.68B US Long portfolio. Pentwater Capital Management Lp has cut its stake in Vmware Inc (NYSE:VMW) and also reduced its holding in Aetna Inc (Call) by 25,000 shares in the quarter, for a total of 500 shares.

For more Esperion Therapeutics, Inc. (NASDAQ:ESPR) news announced recently go to: Seekingalpha.com, Benzinga.com, Nasdaq.com, Nasdaq.com or Seekingalpha.com. The titles are as follows: “Esperion up 8% premarket” announced on October 26, 2018, “74 Biggest Movers From Friday” on November 05, 2018, “Report: Exploring Fundamental Drivers Behind American Vanguard, Pioneer Natural Resources, American States …” with a publish date: November 09, 2018, “Esperion Announces Positive Top-Line Results from Final Pivotal Phase 3 Study of Bempedoic Acid” and the last “Three sell-siders bullish on Kodiak Sciences in premarket analyst action” with publication date: October 29, 2018.

Esperion Therapeutics, Inc. (NASDAQ:ESPR) Ratings Coverage

In total 3 analysts cover Esperion Therapeutics (NASDAQ:ESPR). “Buy” rating has 2, “Sell” are 0, while 1 are “Hold”. 67% are bullish. 3 are the (NASDAQ:ESPR)’s analyst reports since July 11, 2018 according to StockzIntelligence Inc. The company rating was downgraded by Northland Capital on Wednesday, July 11. On Friday, August 17 the company was upgraded by Citigroup.

Esperion Therapeutics, Inc. (NASDAQ:ESPR) Institutional Investors Chart

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.